ALL-IN-ON-GREEN
12.12.2022 07:01:35 CET | Business Wire | Press release
At least 70 cities in Europe can now prevent huge amounts of waste from ending up in the sea. This has been demonstrated in the city of Aarhus in Denmark, where the robot SeaProtectorOne, made by All In On Green, collected over 100,000 pieces of waste from the city’s river in just 20 months. The technology thus shows how much pollution the city is otherwise sending into the marine environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221211005006/en/
Many tonnes of waste flow into the sea from the world’s rivers: A Danish robot minimises this pollution (Photo: Business Wire)
Once waste enters the oceans, removing it is extremely difficult. This is why a Danish robotics invention is tackling the problem before it happens. The robot SeaProtectorOne is installed at the river mouth in Aarhus, where the river flows into the harbour and wider sea. The robot collects the waste—things like plastic cups, facemasks and pizza boxes—before it pollutes the sea. At the same time, it allows boats and other marine vessels to pass by.
SeaProtectorOne could also limit sea pollution from rivers in at least 70 other cities in Europe. This potential has been shown by thorough studies of the cities’ local conditions carried out by the team that has developed SeaProtectorOne. Kim Gulvad Svendsen, COO, Aarhus Municipality, readily shares his positive experience with this new weapon in the fight to prevent sea pollution.
“After the trial period, we were surprised at just how effective the robot was and by how much waste – especially plastic – it removed. This is plastic that will no longer end up in our marine environment. So the robot supports Aarhus Municipality’s sustainability efforts and above all, the UN’s global sustainable development goal no. 14: Life Below Water,” said Kim Gulvad Svendsen.
Every year, the amount of plastic waste that ends in the oceans is equivalent in weight to 57,000 blue whales. At least 90% of the plastic waste that floats around in the oceans, ends in the sea via river systems, according to the periodical Environmental Science.
“Once waste enters the sea it spreads quickly and is difficult to collect. Whereas the current in a river allows for the systematic filtering of waste in a limited area without disturbing fish or birds,” said Peter Grønkjær, Professor of Marine Biology at the Aarhus University.
Mads Tranders Nielsen from All In On Green is the man who invented SeaProtectorOne.
“In an ideal world, every citizen everywhere would learn to always put waste into a waste bin. But we don’t live in an ideal world. The idea for the robot came to me when I saw huge amounts of waste floating in a river in Melbourne. SeaProtectorOne has now shown its worth, even in Aarhus, one of Europe’s greenest cities. So, I’m looking forward to bringing this technology to the rest of the world for the benefit of the marine environment, fish and birds,” said Mads Tranders Nielsen from All In On Green.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221211005006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
